Clinical trials
Completed Phase 2 trials in Italy
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
2,066 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 15 |
| 2001 | 22 |
| 2002 | 35 |
| 2003 | 32 |
| 2004 | 55 |
| 2005 | 64 |
| 2006 | 98 |
| 2007 | 102 |
| 2008 | 100 |
| 2009 | 103 |
| 2010 | 114 |
| 2011 | 131 |
| 2012 | 114 |
| 2013 | 104 |
| 2014 | 108 |
| 2015 | 110 |
| 2016 | 105 |
| 2017 | 115 |
| 2018 | 98 |
| 2019 | 103 |
| 2020 | 80 |
| 2021 | 92 |
| 2022 | 66 |
| 2023 | 34 |
| 2024 | 34 |
| 2025 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 2,066 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Novartis Pharmaceuticals | 127 |
| Hoffmann-La Roche | 115 |
| Bristol-Myers Squibb | 73 |
| Bayer | 66 |
| GlaxoSmithKline | 58 |
| Pfizer | 54 |
| Boehringer Ingelheim | 48 |
| Sanofi | 48 |
| AstraZeneca | 44 |
| European Organisation for Research and Treatment of Cancer - EORTC | 44 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Carcinoma, Non-Small-Cell Lung | 98 |
| Breast Neoplasms | 96 |
| Recurrence | 53 |
| Colorectal Neoplasms | 52 |
| Neoplasms | 50 |
| Neoplasm Metastasis | 44 |
| Melanoma | 37 |
| Multiple Myeloma | 35 |
| Lymphoma, Non-Hodgkin | 33 |
| Ovarian Neoplasms | 33 |
Trials
Showing 1 to 25 of 2,066. Each trial links to its page on Pharma Observatory.
1,966 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.